Matinas BioPharma Holdings, Inc. (MTNB)
2.64
+0.22
(+9.09%)
USD |
NYAM |
Oct 02, 16:00
2.83
+0.19
(+7.20%)
After-Hours: 20:00
Matinas BioPharma Holdings Net Income (Quarterly) : -1.326M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.326M |
| March 31, 2026 | -1.921M |
| December 31, 2025 | -1.912M |
| September 30, 2025 | -2.15M |
| June 30, 2025 | -5.245M |
| March 31, 2025 | -1.656M |
| December 31, 2024 | -8.433M |
| September 30, 2024 | -4.275M |
| June 30, 2024 | -5.719M |
| March 31, 2024 | -5.824M |
| December 31, 2023 | -5.314M |
| September 30, 2023 | -6.055M |
| June 30, 2023 | -6.06M |
| March 31, 2023 | -5.513M |
| December 31, 2022 | -3.635M |
| September 30, 2022 | -5.462M |
| June 30, 2022 | -5.923M |
| March 31, 2022 | -5.978M |
| December 31, 2021 | -6.699M |
| September 30, 2021 | -6.837M |
| June 30, 2021 | -4.791M |
| March 31, 2021 | -4.956M |
| December 31, 2020 | -6.341M |
| September 30, 2020 | -5.450M |
| June 30, 2020 | -5.610M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.046M |
| December 31, 2019 | -5.573M |
| September 30, 2019 | -4.404M |
| June 30, 2019 | -3.345M |
| March 31, 2019 | -4.051M |
| December 31, 2018 | -3.626M |
| September 30, 2018 | -2.936M |
| June 30, 2018 | -3.411M |
| March 31, 2018 | -4.11M |
| December 31, 2017 | -3.628M |
| September 30, 2017 | -3.395M |
| June 30, 2017 | -3.968M |
| March 31, 2017 | -21.24M |
| December 31, 2016 | -1.892M |
| September 30, 2016 | -1.838M |
| June 30, 2016 | -1.624M |
| March 31, 2016 | -2.245M |
| December 31, 2015 | -2.006M |
| September 30, 2015 | -2.155M |
| June 30, 2015 | -2.404M |
| March 31, 2015 | -2.570M |
| December 31, 2014 | -3.044M |
| September 30, 2014 | -2.612M |
| June 30, 2014 | -2.426M |
| March 31, 2014 | -2.139M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.326M |
| EPS Diluted (Quarterly) | -3.105 |
| Enterprise Value | 0.3225M |
| Earnings Yield | -682.3% |
| Normalized Earnings Yield | -705.14 |